SEC Form 4 · accession 0001615774-18-004510
Tonix Pharmaceuticals Holding Corp. · TNXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Seth Lederman
Officer — Chief Executive Officer · Director
Period of report
May 25, 2018
Accepted (ET)
May 30, 2018 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001430306
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value | May 25, 2018 | P | 4,000 | $3.17 | A | 26,700 | I | By 401(k) plan |
| Common Stock, $0.001 par value | holding | — | — | — | 11,166 | D | ||
| Common Stock, $0.001 par value | holding | — | — | — | 45,900 | I | By IRA account | |
| Common Stock, $0.001 par value | holding | — | — | — | 3,100 | I | By spouse | |
| Common Stock, $0.001 par value | holding | — | — | — | 3 | I | By Leder Laboratories, Inc | |
| Common Stock, $0.001 par value | holding | — | — | — | 3 | I | By Starling Pharmaceuticals, Inc. | |
| Common Stock, $0.001 par value | holding | — | — | — | 18,463 | I | By Lederman & Co., LLC | |
| Common Stock, $0.001 par value | holding | — | — | — | 3,246 | I | By L&L Technologies, LLC | |
| Common Stock, $0.001 par value | holding | — | — | — | 5,898 | I | By Targent Pharmaceuticals, LLC |
Table II — derivative securities
No Table II lines on this filing.